



KETAMINE & RELATED COMPOUNDS

INTERNATIONAL CONFERENCE 2024

Conference Program Day 1 – Provisional timings Monday, 25th March

- 11.00** Registration
- 11.30** Anatomy of melancholy – a preconference revision of neuroanatomy relevant to depression
Speaker: Laith Alexander (Kings College, London, UK)
- 12.00** Lunch (not provided)
- 12.40** Welcome and house-keeping
Speaker: Sara Costi (University of Oxford, UK)
- 12.50** Neural mechanism underlying ketamine's rapid, sustained, brain-region- and behavioral-state-specific effects
Speaker: Hailan Hu (Zhejiang University, China)
- 13.40** From neurotoxicity to neuroplasticity: a lifesaving drug that must be used with respect
Speaker: Jonathan Javitt (NRX pharmaceuticals)
- 14.00** IV and subcutaneous R-Ketamine for TRD: phase 1 and 2a (Perception)
Speaker: David Feifel (University of California San Diego, USA)
- 14.30** Refreshment Break
- 15.00** Addiction potential of ketamine enantiomers and metabolites, and of esmethadone
Speaker: Marjorie Levinstein (National Institute on Drug Abuse, USA)
- 15.30** Glutamate and opioid mechanisms of antidepressant response to ketamine (GO-MARK)
Speaker: Luke Jelen (King's College London, UK)
- 16.00** Opioid use reduces placebo response independently of pain in a ketamine depression trial
Speaker: Theresa Lii (Stanford University, USA)
- 16.30** The misuse potential of medicinal (off-label) ketamine: RWE in the US
Speaker: Shahar Almog (University of Florida, USA)



KETAMINE & RELATED COMPOUNDS
INTERNATIONAL CONFERENCE 2024

Conference Program Day 1 – Provisional timings

Monday, 25th March

18.15 Reception at the Blackwell Hall, Weston Library (Broad Street)

19.30- Debate at Holywell Music Room (Holywell Street)
20.15

Motion: “This house believes that oral home treatment with ketamine could be widely and safely used for the treatment of resistant depression”

Speakers For: *Rupert McShane (University of Oxford, UK)*
 Robert Schoevers (Groningen University, The Netherland)

Speakers Against: *Alan Schatzberg (Stanford University, USA)*
 Zoe Cormier (Author and Journalist, UK)

Chair: *Colleen Loo (UNSW Sydney, Australia)*

The Debate is sponsored by Neurocentrx Pharma Ltd



KETAMINE & RELATED COMPOUNDS INTERNATIONAL CONFERENCE 2024

Conference Program Day 2 – Provisional timings

Tuesday, 26^h March

- 09.00** An Open-label Clinical Trial Combining Ketamine Treatment with Written Exposure Therapy for Chronic PTSD
Speaker: Adriana Feder (Icahn School of Medicine at Mount Sinai, USA)
- 09.30** Comorbid PTSD and childhood trauma: impact on ketamine's efficacy in TRD
Speaker: Danica Johnson (University of Toronto, Canada)
- 09.50** Short talk:
Ketamine for depression and PTSD in the military: an untapped opportunity?
Morgan Hardy (RAF Lakenheath, UK)
- 10.00** Prucalopride (5HT₄a agonist) plus ketamine: additive effects on stress
Speaker: Christine Denny (Columbia University, USA)
- 10.30** Refreshment Break
- 11.00** Where are we with the ketamine-opioid story?
Speaker: Alan Schatzberg (Stanford University, USA)
- 11.30** Short talks:
Influence of ketamine on the effect of expectations on perceptual and emotional learning
Lilian Weber (University of Oxford, UK)
Routine EEG monitoring during ketamine treatment: preliminary results
Marco Fabus (University of Oxford, UK)
- 11.50** EEG gamma oscillations as a prognostic marker for IV ketamine in TRD
Speaker: Sanjay Mathew (Baylor College of Medicine, USA)
- 12.20** Development and clinical translation of ultrasonic ketamine uncaging to treat affective disorders
Speaker: Raag Airan (Stanford University, USA)
- 12.40** Lunch



KETAMINE & RELATED COMPOUNDS INTERNATIONAL CONFERENCE 2024

Conference Program Day 2 – Provisional timings

Tuesday, 26^h March

- 13.15** Long-term safety and durable efficacy of esketamine in TRD and ESCAPE-TRD
Speaker: Wayne Drevets (Janssen Pharmaceutical Companies)
- 13.45** Ketamine vs. ECT: implications for clinical practice, policy and future research
Speaker: Amit Anand (Harvard Medical School, USA)
- 14.15** Machine learning to predict response to ECT vs (es)ketamine
Speaker: Michael Henry (Harvard Medical School, USA)
- 14.35** Short talk: IV esketamine in TRD - RWE following induction
Tiago Gill (Centro de Cetamina, Brazil)
- 14.45** Refreshment Break
- 15.15** Mesmer, cardiac surgery, and ketamine: appreciating the power of contextual effects
Speaker: Gerard Sanacora (Yale University, USA)
- 15.45** Ketamine-assisted psychotherapies: a systematic review and historical overview
Speaker: Robert Schoevers (University of Groningen, The Netherlands)
- 16.15** Psychological mechanisms of change in ketamine treatment: two mechanistic studies
Speakers: Celia Morgan (University of Exeter, UK) and Michael Begley, (Devon Partnership Trust, UK)
- 16.35** Implementation of emerging psychedelics: models of support and interventional psychiatry
Speaker: Steve Levine (Compass Pathways)
- 18.45** Pre-dinner drinks – Fellows Garden, Exeter college
- 19.30** Conference Dinner – Exeter College Dining Hall



KETAMINE & RELATED COMPOUNDS
INTERNATIONAL CONFERENCE 2024

Conference Program Day 3 – Provisional timings

Wednesday, 27^h March

- 09.00** Mouse model of anorexia: effects of ketamine in adults and adolescents
Speaker: Chiye Aoki (New York University, USA)
- 09.25** Short talk: Ketamine for depression with Anorexia Nervosa: the EDEN study
Johanna Keeler (King's College London, UK)
- 09.30** RCT of dextromethorphan vs psilocybin: effects in healthy volunteers with history of hallucinogen use
Speaker: David Mathai (Johns Hopkins, USA)
- 10.00** Psilocybin and ketamine: two sides of the same coin?
Speaker: David Nutt (Imperial College London, UK)
- 10.30** Refreshment Break
- 11.00** RCT of ketamine for OCD
Speaker: Peter van Roessel (Stanford University, USA)
- 11.30** Development of a ketamine long-acting injectable microsphere formulation
Speaker: Rachel Galaska (Oakwood Labs, USA)
- 11.45** Adjunctive CLE-100 esketamine tablet for MDD: a phase 2 RCT during COVID (Clexio)
Speaker: Esther Lukasiewicz Hagai (Clexio Bioscience)
- 12.05** Short talks:
Problematic ketamine use and addiction services: a survey - *Rebecca Harding (UCL, UK)*
7T imaging of reward loss and shock 24h after ketamine - *Erdem Pulcu (University of Oxford)*
- 12.25** Lunch



KETAMINE & RELATED COMPOUNDS INTERNATIONAL CONFERENCE 2024

Conference Program Day 2 – Provisional timings

Wednesday, 27^h March

- 13.15** Dose finding study of prolonged release oral ketamine formulation (Ketabon)
Speaker: Hans Eriksson (Ketabon)
- 13.35** Keticap immediate release formulation: phase 1 data (Neurocentrx)
Speakers: Daniel Silman (Kings College, UK)
- 13.55** 7T structure, spectroscopy & fMRI up to 24h post IV ketamine dose in 80 healthy volunteers
Speaker: Meng Li (Jena University Hospital, Germany)
- 14.15** Short talks:
The immediate and delayed effects of ketamine on brain functional dynamics
Nooshin Javaheripour (Jena University Hospital, Germany)
Oral esketamine for bipolar TRD: an open label treatment programme
Jolien Veraart (Groningen University, The Netherlands)
Oral esketamine as an alternative for maintenance ECT in TRD: case series
Jeanine Kamphuis (Groningen University, The Netherlands)
- 14.45** Refreshment Break
- 15.15** RCT of ketamine for depression in Parkinson's disease
Speaker: Sophie Holmes (Yale University, USA)
- 15.35** Pilot RCT of ethosuximide in TRD: efficacy and safety
Speaker: Shaohua Hu (Zhejiang University, China)
- 15.50** Dose finding and target engagement of GM-1020, an oral NMDA-R antagonist (Gilgamesh)
Speaker: Gerard Marek (Gilgamesh Pharma)
- 16.10** Prospective tracking of bladder symptoms in long term ketamine treatment
Speaker: Rupert McShane (University of Oxford, UK)
- 16.25** Cost-utility analysis of treatment initiation with subcutaneous ketamine for TRD from the KADS Study
Speaker: Colleen Loo (University of New South Wales, Sydney, Australia)
- 16.55** Closing remarks
Speaker: Rupert McShane, University of Oxford, UK



KETAMINE & RELATED COMPOUNDS
INTERNATIONAL CONFERENCE 2024

We wish to thank our sponsors:

PLATINUM:



GOLD:



SILVER:

